{"Title": ["Enanta Pharmaceuticals Inc (ENTA) Q2 2020 Earnings Call Transcript", "FDA Decision On BMY's Drug Postponed, ENTA's PBC Study Fails, MGNX Turns Heads", "Will These Pharma Stocks Hit Or Miss Trial Goals? (ITRM, STRO, ENTA)", "AbbVie : EU Approves Change To Marketing Authorization For Maviret", "Enanta Pharmaceuticals Inc (ENTA) Q1 2020 Earnings Call Transcript", "Analysts Anticipate PJP Will Reach $73", "Enanta Pharmaceuticals Becomes Oversold (ENTA)", "How The Pieces Add Up: PBE Targets $62", "Enanta Pharmaceuticals Inc (ENTA) Q2 2020 Earnings Call Transcript", "Enanta Pharmaceuticals' Q4 Results Pulled Down by AbbVie's Sinking HCV Sales", "Enanta Pharmaceuticals Inc (ENTA) Q4 2019 Earnings Call Transcript", "Commit To Buy Enanta Pharmaceuticals At $55, Earn 16.5% Annualized Using Options", "AbbVie Receives FDA Approval Of MAVYRET", "Enanta's Phase 2a Study Of EDP-305 In NASH Hits Goals", "Enanta Pharmaceuticals, Inc. (ENTA) Q2 2019 Earnings Call Transcript", "ENTA Crosses Below Key Moving Average Level", "Validea's Top Five Healthcare Stocks Based On Kenneth Fisher - 12/15/2019", "Notable Two Hundred Day Moving Average Cross - ENTA", "Noteworthy Friday Option Activity: KEX, R, ENTA", "Health Care Sector Update for 03/18/2019: BHVN,EW,ENTA,BSX", "Health Care Sector Update for 03/18/2019: EW,ENTA,BSX", "Notable Friday Option Activity: ENTA, LULU, CBRL", "ENTA Makes Bullish Cross Above Critical Moving Average", "Enanta Pharmaceuticals Inc (ENTA) Q1 2019 Earnings Conference Call Transcript", "Notable Wednesday Option Activity: REGI, AMAT, ENTA", "Enanta Pharmaceuticals (ENTA) Earnings Expected to Grow: Should You Buy?", "Add Up The Pieces: PJP Could Be Worth $80", "Enanta Pharmaceuticals Inc (ENTA) Q4 2018 Earnings Conference Call Transcript", "After-Hours Earnings Report for November 26, 2018 : ENTA, BKE, MTSC, GSM", "Enanta Pharmaceuticals (ENTA) Expected to Beat Earnings Estimates: Should You Buy?", "Commit To Buy Enanta Pharmaceuticals At $80, Earn 13% Annualized Using Options", "Why Enanta Stock Is Still a Strong Buy With Huge Upside", "Enanta Pharmaceuticals (ENTA) Lags Q1 Earnings and Revenue Estimates", "Why Earnings Season Could Be Great for Enanta Pharmaceuticals (ENTA)", "Achieve Life Sciences' Shares Rise on Positive Clinical Data", "5 Biotech Stocks That Could Be the Next Amgen", "2 Stable and 2 Speculative Biotech Stocks to Buy", "Play the Best Sector of Summer With These ETFs & Stocks", "ENTA Crosses Above Average Analyst Target", "Health Care Sector Update for 06/06/2018: ENTA,ITCI,CLRB,ALKS,BIIB", "Oversold Conditions For Enanta Pharmaceuticals (ENTA)", "Why Earnings Season Could Be Great for Enanta Pharmaceuticals (ENTA)", "Achieve Life Sciences' Shares Rise on Positive Clinical Data", "AstraZeneca's Lokelma Gains FDA Nod to Treat Hyperkalemia", "Pfizer's Epilepsy Drug Lyrica Succeeds in Pediatric Study", "Zoetis (ZTS) Inks Deal to Acquire Abaxis for $2 Billion", "Sanofi Eczema Drug Dupixent Succeeds in Adolescents Study", "Roche's Actemra Gets FDA Nod for Subcutaneous Formulation", "Why Enanta Pharmaceuticals (ENTA) Could Shock the Market Soon", "Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down", "Intrexon (XON) Q1 Loss Narrower Than Expected, Revenues Miss", "Endocyte (ECYT) Q1 Loss Narrower Than Expected, Shares Up", "Keryx (KERX) Loss Narrower than Expected in Q1, Sales Beat", "Catalyst (CPRX) Posts In-Line Q1 Loss, Pipeline Progresses", "Ophthotech's (OPHT) Q1 Loss Narrows Y/Y, Zimura in Focus", "VIVUS (VVUS) Q1 Loss Narrower Than Expected, Qsymia Falters", "Celldex (CLDX) Q1 Loss Wider Than Expected, Shares Down", "Geron (GERN) Q1 Loss Narrows Y/Y, Revenues Fall, Shares Down", "This Small Biotech Is Building on a Surprising Success", "FDA Okays Label Expansion of Pacira's Exparel's, Stock Up", "Emergent (EBS) Gains 86.1% in a Year's Time: Here's Why", "Novo Nordisk Obtains Licence for Sickle Cell Disease Program", "Rigel Pharmaceuticals (RIGL) Soars: Stock Adds 8.2% in Session", "Will Agency Growth Aid Booking Holdings (BKNG) Q1 Earnings?", "Sanofi's (SNY) Skin Cancer Candidate Filing Accepted in EU", "Alkermes Sinks as FDA Refuses Depression Drug Review", "Edge Therapeutics Loses Edge on Failure of Late-Stage Study", "Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead?", "Novo Nordisk Poised on Strong Pipeline Amid Competition", "Alexion (ALXN) Gains On Positive Date From Lead Candidate", "ArQule (ARQL) in Focus: Stock Moves 15.6% Higher", "Bio-Path Leukemia Combo Study Shows Positive Early Data", "Sanofi's (SNY) Skin Cancer Candidate Filing Accepted in EU", "Alkermes Sinks as FDA Refuses Depression Drug Review", "Edge Therapeutics Loses Edge on Failure of Late-Stage Study", "Valeant (VRX) Stock Declines 21% YTD: What Lies Ahead?", "Novo Nordisk Poised on Strong Pipeline Amid Competition", "Alexion (ALXN) Gains On Positive Date From Lead Candidate", "ArQule (ARQL) in Focus: Stock Moves 15.6% Higher", "Dermira's Acne Candidate Fails in Pivotal Trials, Shares Sink", "Perrigo (PRGO) Surpassed Earnings in Q4, Revenues Down Y/Y", "Impax (IPXL) Q4 Earnings & Revenues Miss Estimates, Fall Y/Y", "Pacira (PCRX) Posts Earnings in Q4, Revenues in Line", "Sarepta (SRPT) Narrows Q4 Loss, Exondys 51 Sales Impress", "Endo (ENDP) Surpasses Earnings, Revenue Estimates in Q4", "Jazz Pharmaceuticals (JAZZ) Q4 Earnings Miss, Sales Up Y/Y", "Lilly, Boehringer to Expand Jardiance Heart Failure Program", "Perrigo (PRGO) Postpones Q4 Earnings Results, Shares Down", "Endocyte (ECYT) Reports Wider-Than-Estimated Loss in Q4", "Commit To Buy Enanta Pharmaceuticals At $55, Earn 6% Annualized Using Options", "Corcept's (CORT) Earnings and Sales Meet Estimates in Q4", "AbbVie Presents New Data on Upadacitinib for Crohn's Disease", "Stocks To Watch: Alkermes Sees Relative Strength Rating Rise To 85", "Alkermes Gets IBD Stock Rating Upgrade", "AMAG Pharma (AMAG) Beats on Q4 Earnings, Misses on Revenues", "Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong", "Acorda Therapeutics Joins Rank Of Stocks With RS Ratings Over 90", "Puma Biotechnology Scores Relative Strength Rating Upgrade; Hits Key Threshold", "Portola Pharmaceuticals Getting Closer To Key Technical Benchmark", "Alder Biopharmaceuticals Shows Rising Relative Strength; Still Shy Of Key Benchmark", "AVEO (AVEO) to Get $2 Million from EUSA Pharma for Fotivda", "Thursday's ETF Movers: GDXJ, XBI", "Zoetis (ZTS) Beats on Q4 Earnings & Sales, Gives 2018 View", "Shire (SHPG) Q4 Earnings Beat, Immunology Franchise Strong", "Acorda Therapeutics Joins Rank Of Stocks With RS Ratings Over 90", "Will Conatus Key Candidate Emricasan Drive Long-Term Growth?", "AbbVie's HCV Combo Drug Mavyret Clinches Approval in Canada", "Zacks.com featured highlights: Columbus McKinnon, The New York Times, Advanced Accelerator Applications, Enanta Pharmaceuticals and Caesars Entertainment", "Buy These 5 Stocks on New Analyst Coverage", "After-Hours Earnings Report for November 20, 2017 : INTU, A, PANW, VIPS, BECN, ZTO, URBN, CUB, RAVN, GBDC, ENTA, GLAD", "Health Care Sector Update for 07/28/2017: ENTA, ABBV, CYTR, ATNM", "AbbVie's HCV Combo Drug Gets Positive CHMP Opinion in EU", "The Best Hep C Drug Stock to Buy in 2017", "AbbVie (ABBV) Presents Positive Data on HCV Combination Drug", "AbbVie (ABBV) HCV Regimen Gets Priority Review in Canada", "AbbVie's HCV Regimen Okayed for Accelerated Assessment", "Surging Earnings Estimates Signal Good News for Enanta Pharma (ENTA)", "4 Drug Stocks in Focus this World Hepatitis Day", "After-Hours Earnings Report for November 21, 2016 : PANW, CPRT, VIPS, BRCD, SINA, WB, JACK, DY, BECN, ENTA, PNNT, SBLK", "Health Care Sector Update for 11/11/2016: ENTA", "AbbVie: HCV Regimen Obtains Breakthrough Therapy Status", "5 Biotech Stocks to Watch as Interest in NASH Increases", "Health Care Sector Update for 04/14/2016: AMGN, MRK, ABT, PFE, JNJ, ABBV, ENTA, SNTA", "Health Care Sector Update for 12/02/2015: ENTA, REPH, ACHC", "After-Hours Earnings Report for November 23, 2015 : PANW, CPRT, BRCD, POST, DY, CUB, ENTA, CO, TOUR, GLAD, PPSI", "Enanta Pharmaceuticals Releases Results", "After-Hours Earnings Report for November 21, 2016 : PANW, CPRT, VIPS, BRCD, SINA, WB, JACK, DY, BECN, ENTA, PNNT, SBLK", "Health Care Sector Update for 11/11/2016: ENTA", "Enanta Pharmaceuticals (ENTA) Jumps: Stock Rises 5.1% - Tale of the Tape", "Five Free-Cash All-Stars With Guru Strategy Approval", "10 Most Profitable Companies in Healthcare", "Should You Buy Enanta Pharmaceuticals (ENTA) Ahead of Earnings? - Tale of the Tape", "3 Beaten Down Healthcare Stocks Poised for a Turnaround", "Here's Why Enanta Pharmaceuticals Stock Beat the Downtrend in July", "Health Care Sector Update for 02/05/2015: RXDX, ENTA, AZN", "Enanta Pharmaceuticals (ENTA) Falls: Stock Tanks 10% - Tale of the Tape", "3 Biotech Stocks With a Higher Profit Margin Than Gilead Sciences, Inc.", "Commit To Purchase Enanta Pharmaceuticals At $42, Earn 13.5% Annualized Using Options", "The Hepatitis C Drug Developer That Crushed Gilead Sciences, Inc. in 2014 (Hint: It's Not AbbVie)", "AbbVie Inc. Throws First Punch in Hep C Price War With Gilead Sciences, Inc.", "1 Big FDA Decision I'm Watching This Month", "Does This Small Biotech Have the Making of a Blockbuster?", "Company News for November 25, 2014 - Corporate Summary", "Health Care Sector Update for 11/24/2014: TTPH, ENTA", "Can Partnering To Fight Hepatitis C Pay At Enanta?", "Why AbbVie Inc.'s Game-Changing New Drug Could Be a Serious Threat to Gilead Sciences Inc.", "ImmunoGen (IMGN) in Focus: Stock Rallies 14% - Tale of the Tape", "AbbVie Drops Shire Deal, Announces Buyback, Ups Dividend - Analyst Blog", "ChemoCentryx, Inc. (CCXI) in Focus: Stock Rises 9.6% - Tale of the Tape", "5 Stocks to Watch Closely for the Rest of 2014", "Pacira (PCRX) Reveals Additional Safety Data on Exparel - Analyst Blog", "Why Is Sanofi Betting on MannKind Corporation's Afrezza?", "Commit To Purchase Enanta Pharmaceuticals At $37, Earn 16.4% Annualized Using Options", "A Company's First Profit Can Mean Big Profits to Investors - Screen of the Week", "Galmed's Aramchol Gets Fast-Track Designation in the U.S. - Analyst Blog", "3 Reasons Bristol-Myers Squibb's Stock Could Fall", "What Makes Durata Therapeutics (DRTX) a Strong Sell? - Tale of the Tape", "Tetraphase (TTPH) Crumbles: Stock Tanks by 15% - Tale of the Tape", "BioCryst Pharmaceuticals (BCRX) Jumps: Stock Adds 5.4% in Session - Tale of the Tape", "Flamel Technologies SA (FLML) Soars: Stock Rises 10.9% - Tale of the Tape", "IGI, Laboratories (IG) in Focus: Stock Rises 10.6% - Tale of the Tape", "AcelRx Pharmaceuticals (ACRX) Soars: Stock Adds 6.8% in Session - Tale of the Tape", "Pharmacyclics (PCYC) Jumps: Stock Rises 15% - Tale of the Tape", "QLT Inc. (QLTI) Soars: Stock Adds 7.9% in Session - Tale of the Tape", "TESARO (TSRO) Slips on Wider-than-Expected Q2 Loss - Analyst Blog", "OncoGenex Pharmaceuticals (OGXI) Soars: Stock Up 8.2% - Tale of the Tape", "ImmunoGen (IMGN) Soars: Stock Up 8.8% - Tale of the Tape", "Merck Presents Positive Trial Results For Cancer Drug", "AbbVie Up on HCV Filing in Canada - Analyst Blog", "Pre-Market Earnings Report for May 12, 2014 : CXO, DRH, EVEP, INN, ZINC, BPI, ENTA, TICC, INO, FLML, SPNS, AGM", "ARIAD's Q1 Loss Narrows - Analyst Blog", "Wider-than-Expected Loss at Auxilium - Analyst Blog", "Endocyte, Inc. (ECYT) in Focus: Stock Rises 5.6% - Tale of the Tape", "AcelRx Pharmaceuticals (ACRX) Jumps: Stock Adds 11.7% in Session - Tale of the Tape", "Enanta (ENTA) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape", "Auxilium Pharma Cuts Guidance - Analyst Blog", "Synergy Pharmaceuticals (SGYP) Jumps: Stock Up 10.9% - Tale of the Tape", "Dr. Reddy's Launches Generic Antara - Analyst Blog", "AbbVie Files for HCV Combination Therapy in U.S. - Analyst Blog", "Karyopharm Starts Phase I Study - Analyst Blog", "Galectin Therapeutics Rises on GR-MD-02 Update - Analyst Blog", "Endo International plc (ENDP) Jumps: Stock Rises 5.4% - Tale of the Tape", "Enanta (ENTA) Sees Hammer Chart Pattern: Time to Buy? - Tale of the Tape", "Auxilium Pharma Cuts Guidance - Analyst Blog", "Synergy Pharmaceuticals (SGYP) Jumps: Stock Up 10.9% - Tale of the Tape", "Has A Streamlined FDA Raised The Value Of Drug Stocks?", "Positive Data on AbbVie's HCV Program - Analyst Blog", "Commit To Purchase Enanta Pharmaceuticals At $35, Earn 20.7% Annualized Using Options", "AbbVie HCV Combination Therapy Data Looks Good - Analyst Blog", "Dr. Reddy's Launches Generic Lunesta - Analyst Blog", "Sector Update: Healthcare Shares Fairly Flat; Acorda Q4 Earnings Top Street View", "Enanta (ENTA) Worth Watching: Stock Rises 13.4% - Tale of the Tape", "Update on Amarin's Vascepa - Analyst Blog", "Update on NVO's Victoza - Analyst Blog", "Sucampo Reports Data - Analyst Blog", "EU Approves Actelion's Opsumit - Analyst Blog", "Strength Seen in Enanta Pharmaceuticals (ENTA): Stock Soars 28.6% - Tale of the Tape", "Sector Update: Healthcare", "Good News for Apricus from Italy - Analyst Blog", "Continuation of ARIAD's Iclusig in EU - Analyst Blog", "Prescription for Profit - Zacks Industry Rank Analysis", "Zacks #1 Rank Additions for Wednesday - Tale of the Tape", "US IPO Weekly Recap: Seven deals price, six new filers", "One US IPO planned for the week of Mar 25", "Enanta Pharmaceuticals prices IPO at $14, the low end of the range", "Enanta Pharmaceuticals (ENTA) Looks Good: Stock Adds 6.2% - Tale of the Tape", "US IPO calendar heats up with seven deals set to price next week", "Biotech Enanta Pharmaceuticals sets terms for $60 million IPO", "9 US IPOs planned for the week of Mar 18"], "Elapsed Time": ["MAY 7, 2020", "MAY 6, 2020", "APR 22, 2020", "MAR 6, 2020", "FEB 6, 2020", "JAN 24, 2020", "JAN 13, 2020", "DEC 24, 2019", "MAY 7, 2020", "NOV 22, 2019", "NOV 21, 2019", "NOV 20, 2019", "SEP 26, 2019", "SEP 26, 2019", "AUG 7, 2019", "JUL 12, 2019", "DEC 15, 2019", "JUN 14, 2019", "APR 26, 2019", "MAR 18, 2019", "MAR 18, 2019", "MAR 8, 2019", "FEB 8, 2019", "FEB 6, 2019", "JUN 26, 2019", "JAN 30, 2019", "DEC 25, 2018", "NOV 26, 2018", "NOV 26, 2018", "NOV 19, 2018", "AUG 22, 2018", "AUG 13, 2018", "FEB 6, 2019", "AUG 2, 2018", "JUN 27, 2018", "JUN 27, 2018", "JUN 15, 2018", "JUN 8, 2018", "JUN 7, 2018", "JUN 6, 2018", "AUG 8, 2018", "AUG 2, 2018", "JUN 27, 2018", "MAY 21, 2018", "MAY 18, 2018", "MAY 17, 2018", "MAY 16, 2018", "MAY 15, 2018", "JUN 1, 2018", "MAY 11, 2018", "MAY 11, 2018", "MAY 11, 2018", "MAY 11, 2018", "MAY 10, 2018", "MAY 10, 2018", "MAY 10, 2018", "MAY 11, 2018", "MAY 11, 2018", "APR 24, 2018", "APR 9, 2018", "APR 6, 2018", "APR 6, 2018", "APR 5, 2018", "MAY 8, 2018", "APR 3, 2018", "APR 3, 2018", "APR 2, 2018", "MAR 22, 2018", "MAR 21, 2018", "MAR 16, 2018", "MAR 16, 2018", "APR 4, 2018", "APR 3, 2018", "APR 3, 2018", "APR 2, 2018", "MAR 22, 2018", "MAR 21, 2018", "MAR 16, 2018", "MAR 16, 2018", "MAR 6, 2018", "MAR 2, 2018", "MAR 2, 2018", "MAR 2, 2018", "MAR 2, 2018", "FEB 28, 2018", "FEB 28, 2018", "MAR 8, 2018", "FEB 27, 2018", "FEB 27, 2018", "FEB 23, 2018", "FEB 23, 2018", "FEB 19, 2018", "FEB 16, 2018", "FEB 16, 2018", "FEB 28, 2018", "FEB 15, 2018", "FEB 15, 2018", "FEB 15, 2018", "FEB 15, 2018", "FEB 15, 2018", "FEB 14, 2018", "FEB 8, 2018", "FEB 15, 2018", "FEB 15, 2018", "FEB 15, 2018", "AUG 21, 2017", "AUG 18, 2017", "AUG 4, 2017", "AUG 3, 2017", "NOV 20, 2017", "JUL 28, 2017", "JUN 27, 2017", "JUN 8, 2017", "APR 21, 2017", "FEB 2, 2017", "JAN 25, 2017", "NOV 25, 2016", "JUL 28, 2017", "NOV 21, 2016", "NOV 11, 2016", "OCT 3, 2016", "SEP 22, 2016", "APR 14, 2016", "DEC 2, 2015", "NOV 23, 2015", "NOV 22, 2016", "NOV 21, 2016", "AUG 5, 2015", "JUL 28, 2015", "JUN 30, 2015", "MAY 7, 2015", "MAY 6, 2015", "APR 18, 2015", "AUG 12, 2015", "FEB 5, 2015", "FEB 3, 2015", "JAN 3, 2015", "DEC 30, 2014", "DEC 24, 2014", "DEC 23, 2014", "DEC 4, 2014", "FEB 7, 2015", "NOV 25, 2014", "NOV 24, 2014", "NOV 24, 2014", "NOV 7, 2014", "OCT 21, 2014", "OCT 21, 2014", "OCT 17, 2014", "DEC 1, 2014", "OCT 14, 2014", "OCT 6, 2014", "OCT 1, 2014", "SEP 30, 2014", "SEP 24, 2014", "SEP 4, 2014", "AUG 13, 2014", "OCT 17, 2014", "AUG 5, 2014", "AUG 5, 2014", "AUG 4, 2014", "AUG 1, 2014", "JUL 30, 2014", "JUL 30, 2014", "JUL 30, 2014", "AUG 8, 2014", "JUL 21, 2014", "JUN 2, 2014", "MAY 28, 2014", "MAY 9, 2014", "MAY 8, 2014", "MAY 6, 2014", "MAY 6, 2014", "JUL 21, 2014", "MAY 1, 2014", "APR 30, 2014", "APR 25, 2014", "APR 23, 2014", "APR 23, 2014", "APR 22, 2014", "APR 21, 2014", "MAY 2, 2014", "MAY 1, 2014", "APR 30, 2014", "APR 25, 2014", "APR 17, 2014", "APR 14, 2014", "MAR 10, 2014", "MAR 4, 2014", "APR 17, 2014", "FEB 13, 2014", "FEB 3, 2014", "DEC 27, 2013", "DEC 26, 2013", "DEC 26, 2013", "DEC 24, 2013", "DEC 11, 2013", "FEB 13, 2014", "NOV 26, 2013", "NOV 25, 2013", "NOV 19, 2013", "OCT 2, 2013", "MAR 25, 2013", "MAR 25, 2013", "MAR 20, 2013", "NOV 26, 2013", "MAR 12, 2013", "MAR 5, 2013", "MAR 18, 2013"], "Published Date": [], "Link": ["https://www.nasdaq.com/articles/enanta-pharmaceuticals-inc-enta-q2-2020-earnings-call-transcript-2020-05-07", "https://www.nasdaq.com/articles/fda-decision-on-bmys-drug-postponed-entas-pbc-study-fails-mgnx-turns-heads-2020-05-06", "https://www.nasdaq.com/articles/will-these-pharma-stocks-hit-or-miss-trial-goals-itrm-stro-enta-2020-04-22", "https://www.nasdaq.com/articles/abbvie-%3A-eu-approves-change-to-marketing-authorization-for-maviret-2020-03-06", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-inc-enta-q1-2020-earnings-call-transcript-2020-02-07", "https://www.nasdaq.com/articles/analysts-anticipate-pjp-will-reach-%2473-2020-01-24", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-becomes-oversold-enta-2020-01-13", "https://www.nasdaq.com/articles/how-the-pieces-add-up%3A-pbe-targets-%2462-2019-12-24", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-inc-enta-q2-2020-earnings-call-transcript-2020-05-07", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-q4-results-pulled-down-by-abbvies-sinking-hcv-sales-2019-11-22", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-inc-enta-q4-2019-earnings-call-transcript-2019-11-22", "https://www.nasdaq.com/articles/commit-to-buy-enanta-pharmaceuticals-at-%2455-earn-16.5-annualized-using-options-2019-11-20", "https://www.nasdaq.com/articles/abbvie-receives-fda-approval-of-mavyret-2019-09-26", "https://www.nasdaq.com/articles/enantas-phase-2a-study-of-edp-305-in-nash-hits-goals-2019-09-26", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-inc.-enta-q2-2019-earnings-call-transcript-2019-08-07", "https://www.nasdaq.com/articles/enta-crosses-below-key-moving-average-level-2019-07-12", "https://www.nasdaq.com/articles/valideas-top-five-healthcare-stocks-based-on-kenneth-fisher-12-15-2019-2019-12-15", "https://www.nasdaq.com/articles/notable-two-hundred-day-moving-average-cross-enta-2019-06-14", "https://www.nasdaq.com/articles/noteworthy-friday-option-activity-kex-r-enta-2019-04-26", "https://www.nasdaq.com/articles/health-care-sector-update-03182019-bhvnewentabsx-2019-03-18", "https://www.nasdaq.com/articles/health-care-sector-update-03182019-ewentabsx-2019-03-18", "https://www.nasdaq.com/articles/notable-friday-option-activity-enta-lulu-cbrl-2019-03-08", "https://www.nasdaq.com/articles/enta-makes-bullish-cross-above-critical-moving-average-2019-02-08", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-inc-enta-q1-2019-earnings-conference-call-transcript-2019-02-06", "https://www.nasdaq.com/articles/notable-wednesday-option-activity%3A-regi-amat-enta-2019-06-26", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-enta-earnings-expected-to-grow%3A-should-you-buy-2019-01-30", "https://www.nasdaq.com/articles/add-pieces-pjp-could-be-worth-80-2018-12-25", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-inc-enta-q4-2018-earnings-conference-call-transcript-2018-11-26", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-26-2018-enta-bke-mtsc-gsm-2018-11-26", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-enta-expected-to-beat-earnings-estimates%3A-should-you-buy-2018-11-19", "https://www.nasdaq.com/articles/commit-buy-enanta-pharmaceuticals-80-earn-13-annualized-using-options-2018-08-22", "https://www.nasdaq.com/articles/why-enanta-stock-still-strong-buy-huge-upside-2018-08-13", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-enta-lags-q1-earnings-and-revenue-estimates-2019-02-06", "https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-enanta-pharmaceuticals-enta-2018-08-02", "https://www.nasdaq.com/articles/achieve-life-sciences-shares-rise-on-positive-clinical-data-2018-06-27", "https://www.nasdaq.com/articles/5-biotech-stocks-that-could-be-the-next-amgen-2018-06-27", "https://www.nasdaq.com/articles/2-stable-and-2-speculative-biotech-stocks-buy-2018-06-15", "https://www.nasdaq.com/articles/play-best-sector-summer-these-etfs-stocks-2018-06-08", "https://www.nasdaq.com/articles/enta-crosses-above-average-analyst-target-2018-06-07", "https://www.nasdaq.com/articles/health-care-sector-update-06062018-entaitciclrbalksbiib-2018-06-06", "https://www.nasdaq.com/articles/oversold-conditions-enanta-pharmaceuticals-enta-2018-08-08", "https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-enanta-pharmaceuticals-enta-2018-08-02", "https://www.nasdaq.com/articles/achieve-life-sciences-shares-rise-on-positive-clinical-data-2018-06-27", "https://www.nasdaq.com/articles/astrazenecas-lokelma-gains-fda-nod-to-treat-hyperkalemia-2018-05-21", "https://www.nasdaq.com/articles/pfizers-epilepsy-drug-lyrica-succeeds-in-pediatric-study-2018-05-18", "https://www.nasdaq.com/articles/zoetis-zts-inks-deal-to-acquire-abaxis-for-%242-billion-2018-05-17", "https://www.nasdaq.com/articles/sanofi-eczema-drug-dupixent-succeeds-in-adolescents-study-2018-05-16", "https://www.nasdaq.com/articles/roches-actemra-gets-fda-nod-for-subcutaneous-formulation-2018-05-15", "https://www.nasdaq.com/articles/why-enanta-pharmaceuticals-enta-could-shock-the-market-soon-2018-06-01", "https://www.nasdaq.com/articles/geron-gern-q1-loss-narrows-y-y-revenues-fall-shares-down-2018-05-11", "https://www.nasdaq.com/articles/intrexon-xon-q1-loss-narrower-than-expected-revenues-miss-2018-05-11", "https://www.nasdaq.com/articles/endocyte-ecyt-q1-loss-narrower-than-expected-shares-up-2018-05-11", "https://www.nasdaq.com/articles/keryx-kerx-loss-narrower-than-expected-in-q1-sales-beat-2018-05-11", "https://www.nasdaq.com/articles/catalyst-cprx-posts-in-line-q1-loss-pipeline-progresses-2018-05-10", "https://www.nasdaq.com/articles/ophthotechs-opht-q1-loss-narrows-y-y-zimura-in-focus-2018-05-10", "https://www.nasdaq.com/articles/vivus-vvus-q1-loss-narrower-than-expected-qsymia-falters-2018-05-10", "https://www.nasdaq.com/articles/celldex-cldx-q1-loss-wider-than-expected-shares-down-2018-05-11", "https://www.nasdaq.com/articles/geron-gern-q1-loss-narrows-y-y-revenues-fall-shares-down-2018-05-11", "https://www.nasdaq.com/articles/small-biotech-building-surprising-success-2018-04-24", "https://www.nasdaq.com/articles/fda-okays-label-expansion-of-paciras-exparels-stock-up-2018-04-09", "https://www.nasdaq.com/articles/emergent-ebs-gains-86.1-in-a-years-time%3A-heres-why-2018-04-06", "https://www.nasdaq.com/articles/novo-nordisk-obtains-licence-for-sickle-cell-disease-program-2018-04-06", "https://www.nasdaq.com/articles/rigel-pharmaceuticals-rigl-soars%3A-stock-adds-8.2-in-session-2018-04-05", "https://www.nasdaq.com/articles/will-agency-growth-aid-booking-holdings-bkng-q1-earnings-2018-05-08", "https://www.nasdaq.com/articles/sanofis-sny-skin-cancer-candidate-filing-accepted-in-eu-2018-04-03", "https://www.nasdaq.com/articles/alkermes-sinks-as-fda-refuses-depression-drug-review-2018-04-03", "https://www.nasdaq.com/articles/edge-therapeutics-loses-edge-on-failure-of-late-stage-study-2018-04-02", "https://www.nasdaq.com/articles/valeant-vrx-stock-declines-21-ytd%3A-what-lies-ahead-2018-03-22", "https://www.nasdaq.com/articles/novo-nordisk-poised-on-strong-pipeline-amid-competition-2018-03-21", "https://www.nasdaq.com/articles/alexion-alxn-gains-on-positive-date-from-lead-candidate-2018-03-16", "https://www.nasdaq.com/articles/arqule-arql-in-focus%3A-stock-moves-15.6-higher-2018-03-16", "https://www.nasdaq.com/articles/bio-path-leukemia-combo-study-shows-positive-early-data-2018-04-04", "https://www.nasdaq.com/articles/sanofis-sny-skin-cancer-candidate-filing-accepted-in-eu-2018-04-03", "https://www.nasdaq.com/articles/alkermes-sinks-as-fda-refuses-depression-drug-review-2018-04-03", "https://www.nasdaq.com/articles/edge-therapeutics-loses-edge-on-failure-of-late-stage-study-2018-04-02", "https://www.nasdaq.com/articles/valeant-vrx-stock-declines-21-ytd%3A-what-lies-ahead-2018-03-22", "https://www.nasdaq.com/articles/novo-nordisk-poised-on-strong-pipeline-amid-competition-2018-03-21", "https://www.nasdaq.com/articles/alexion-alxn-gains-on-positive-date-from-lead-candidate-2018-03-16", "https://www.nasdaq.com/articles/arqule-arql-in-focus%3A-stock-moves-15.6-higher-2018-03-16", "https://www.nasdaq.com/articles/dermiras-acne-candidate-fails-in-pivotal-trials-shares-sink-2018-03-06", "https://www.nasdaq.com/articles/perrigo-prgo-surpassed-earnings-in-q4-revenues-down-y-y-2018-03-02", "https://www.nasdaq.com/articles/impax-ipxl-q4-earnings-revenues-miss-estimates-fall-y-y-2018-03-02", "https://www.nasdaq.com/articles/pacira-pcrx-posts-earnings-in-q4-revenues-in-line-2018-03-02", "https://www.nasdaq.com/articles/sarepta-srpt-narrows-q4-loss-exondys-51-sales-impress-2018-03-02", "https://www.nasdaq.com/articles/endo-endp-surpasses-earnings-revenue-estimates-in-q4-2018-02-28", "https://www.nasdaq.com/articles/jazz-pharmaceuticals-jazz-q4-earnings-miss-sales-up-y-y-2018-02-28", "https://www.nasdaq.com/articles/lilly-boehringer-to-expand-jardiance-heart-failure-program-2018-03-08", "https://www.nasdaq.com/articles/perrigo-prgo-postpones-q4-earnings-results-shares-down-2018-02-27", "https://www.nasdaq.com/articles/endocyte-ecyt-reports-wider-than-estimated-loss-in-q4-2018-02-27", "https://www.nasdaq.com/articles/commit-buy-enanta-pharmaceuticals-55-earn-6-annualized-using-options-2018-02-23", "https://www.nasdaq.com/articles/corcepts-cort-earnings-and-sales-meet-estimates-in-q4-2018-02-23", "https://www.nasdaq.com/articles/abbvie-presents-new-data-on-upadacitinib-for-crohns-disease-2018-02-19", "https://www.nasdaq.com/articles/stocks-watch-alkermes-sees-relative-strength-rating-rise-85-2018-02-16", "https://www.nasdaq.com/articles/alkermes-gets-ibd-stock-rating-upgrade-2018-02-16", "https://www.nasdaq.com/articles/amag-pharma-amag-beats-on-q4-earnings-misses-on-revenues-2018-02-28", "https://www.nasdaq.com/articles/shire-shpg-q4-earnings-beat-immunology-franchise-strong-2018-02-15", "https://www.nasdaq.com/articles/acorda-therapeutics-joins-rank-stocks-rs-ratings-over-90-2018-02-15", "https://www.nasdaq.com/articles/puma-biotechnology-scores-relative-strength-rating-upgrade-hits-key-threshold-2018-02-15", "https://www.nasdaq.com/articles/portola-pharmaceuticals-getting-closer-key-technical-benchmark-2018-02-15", "https://www.nasdaq.com/articles/alder-biopharmaceuticals-shows-rising-relative-strength-still-shy-key-benchmark-2018-02-15", "https://www.nasdaq.com/articles/aveo-aveo-to-get-%242-million-from-eusa-pharma-for-fotivda-2018-02-14", "https://www.nasdaq.com/articles/thursdays-etf-movers-gdxj-xbi-2018-02-08", "https://www.nasdaq.com/articles/zoetis-zts-beats-on-q4-earnings-sales-gives-2018-view-2018-02-15", "https://www.nasdaq.com/articles/shire-shpg-q4-earnings-beat-immunology-franchise-strong-2018-02-15", "https://www.nasdaq.com/articles/acorda-therapeutics-joins-rank-stocks-rs-ratings-over-90-2018-02-15", "https://www.nasdaq.com/articles/will-conatus-key-candidate-emricasan-drive-long-term-growth-2017-08-21", "https://www.nasdaq.com/articles/abbvies-hcv-combo-drug-mavyret-clinches-approval-in-canada-2017-08-18", "https://www.nasdaq.com/articles/zacks.com-featured-highlights%3A-columbus-mckinnon-the-new-york-times-advanced-accelerator", "https://www.nasdaq.com/articles/buy-these-5-stocks-on-new-analyst-coverage-2017-08-03", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-20-2017-intu-panw-vips-becn-zto-urbn-cub-ravn-gbdc", "https://www.nasdaq.com/articles/health-care-sector-update-07282017-enta-abbv-cytr-atnm-2017-07-28", "https://www.nasdaq.com/articles/abbvies-hcv-combo-drug-gets-positive-chmp-opinion-in-eu-2017-06-27", "https://www.nasdaq.com/articles/best-hep-c-drug-stock-buy-2017-2017-06-08", "https://www.nasdaq.com/articles/abbvie-abbv-presents-positive-data-on-hcv-combination-drug-2017-04-21", "https://www.nasdaq.com/articles/abbvie-abbv-hcv-regimen-gets-priority-review-in-canada-2017-02-02", "https://www.nasdaq.com/articles/abbvies-hcv-regimen-okayed-for-accelerated-assessment-2017-01-25", "https://www.nasdaq.com/articles/surging-earnings-estimates-signal-good-news-for-enanta-pharma-enta-2016-11-25", "https://www.nasdaq.com/articles/4-drug-stocks-focus-world-hepatitis-day-2017-07-28", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-21-2016-panw-cprt-vips-brcd-sina-wb-jack-dy-becn-enta", "https://www.nasdaq.com/articles/health-care-sector-update-11112016-enta-2016-11-11", "https://www.nasdaq.com/articles/abbvie%3A-hcv-regimen-obtains-breakthrough-therapy-status-2016-10-03", "https://www.nasdaq.com/articles/5-biotech-stocks-watch-interest-nash-increases-2016-09-22", "https://www.nasdaq.com/articles/health-care-sector-update-04142016-amgn-mrk-abt-pfe-jnj-abbv-enta-snta-2016-04-14", "https://www.nasdaq.com/articles/health-care-sector-update-12022015-enta-reph-achc-2015-12-02", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-23-2015-panw-cprt-brcd-post-dy-cub-enta-co-tour-glad", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-releases-results-2016-11-22", "https://www.nasdaq.com/articles/after-hours-earnings-report-november-21-2016-panw-cprt-vips-brcd-sina-wb-jack-dy-becn-enta", "https://www.nasdaq.com/articles/why-earnings-season-could-be-great-for-enanta-pharmaceuticals-enta-tale-of-the-tape-2015", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-enta-jumps%3A-stock-rises-5.1-tale-of-the-tape-2015-07-28", "https://www.nasdaq.com/articles/five-free-cash-all-stars-guru-strategy-approval-2015-06-30", "https://www.nasdaq.com/articles/10-most-profitable-companies-healthcare-2015-05-07", "https://www.nasdaq.com/articles/should-you-buy-enanta-pharmaceuticals-enta-ahead-of-earnings-tale-of-the-tape-2015-05-06", "https://www.nasdaq.com/articles/3-beaten-down-healthcare-stocks-poised-turnaround-2015-04-18", "https://www.nasdaq.com/articles/heres-why-enanta-pharmaceuticals-stock-beat-downtrend-july-2015-08-12", "https://www.nasdaq.com/articles/health-care-sector-update-02052015-rxdx-enta-azn-2015-02-05", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-enta-falls%3A-stock-tanks-10-tale-of-the-tape-2015-02-03", "https://www.nasdaq.com/articles/3-biotech-stocks-higher-profit-margin-gilead-sciences-inc-2015-01-03", "https://www.nasdaq.com/articles/commit-purchase-enanta-pharmaceuticals-42-earn-135-annualized-using-options-2014-12-30", "https://www.nasdaq.com/articles/hepatitis-c-drug-developer-crushed-gilead-sciences-inc-2014-hint-its-not-abbvie-2014-12-24", "https://www.nasdaq.com/articles/abbvie-inc-throws-first-punch-hep-c-price-war-gilead-sciences-inc-2014-12-23", "https://www.nasdaq.com/articles/1-big-fda-decision-im-watching-month-2014-12-04", "https://www.nasdaq.com/articles/does-small-biotech-have-making-blockbuster-2015-02-07", "https://www.nasdaq.com/articles/company-news-for-november-25-2014-corporate-summary-2014-11-25", "https://www.nasdaq.com/articles/health-care-sector-update-11242014-ttph-enta-2014-11-24", "https://www.nasdaq.com/articles/can-partnering-fight-hepatitis-c-pay-enanta-2014-11-24", "https://www.nasdaq.com/articles/why-abbvie-incs-game-changing-new-drug-could-be-serious-threat-gilead-sciences-inc-2014-11", "https://www.nasdaq.com/articles/immunogen-imgn-in-focus%3A-stock-rallies-14-tale-of-the-tape-2014-10-21", "https://www.nasdaq.com/articles/abbvie-drops-shire-deal-announces-buyback-ups-dividend-analyst-blog-2014-10-21", "https://www.nasdaq.com/articles/chemocentryx-inc.-ccxi-in-focus%3A-stock-rises-9.6-tale-of-the-tape-2014-10-17", "https://www.nasdaq.com/articles/5-stocks-watch-closely-rest-2014-2014-12-01", "https://www.nasdaq.com/articles/pacira-pcrx-reveals-additional-safety-data-on-exparel-analyst-blog-2014-10-14", "https://www.nasdaq.com/articles/why-sanofi-betting-mannkind-corporations-afrezza-2014-10-06", "https://www.nasdaq.com/articles/commit-purchase-enanta-pharmaceuticals-37-earn-164-annualized-using-options-2014-10-01", "https://www.nasdaq.com/articles/companys-first-profit-can-mean-big-profits-investors-screen-week-2014-09-30", "https://www.nasdaq.com/articles/galmeds-aramchol-gets-fast-track-designation-in-the-u.s.-analyst-blog-2014-09-24", "https://www.nasdaq.com/articles/3-reasons-bristol-myers-squibbs-stock-could-fall-2014-09-04", "https://www.nasdaq.com/articles/what-makes-durata-therapeutics-drtx-a-strong-sell-tale-of-the-tape-2014-08-13", "https://www.nasdaq.com/articles/tetraphase-ttph-crumbles%3A-stock-tanks-by-15-tale-of-the-tape-2014-10-17", "https://www.nasdaq.com/articles/biocryst-pharmaceuticals-bcrx-jumps%3A-stock-adds-5.4-in-session-tale-of-the-tape-2014-08-05", "https://www.nasdaq.com/articles/flamel-technologies-sa-flml-soars%3A-stock-rises-10.9-tale-of-the-tape-2014-08-05", "https://www.nasdaq.com/articles/igi-laboratories-ig-in-focus%3A-stock-rises-10.6-tale-of-the-tape-2014-08-04", "https://www.nasdaq.com/articles/acelrx-pharmaceuticals-acrx-soars%3A-stock-adds-6.8-in-session-tale-of-the-tape-2014-08-01", "https://www.nasdaq.com/articles/pharmacyclics-pcyc-jumps%3A-stock-rises-15-tale-of-the-tape-2014-07-30", "https://www.nasdaq.com/articles/qlt-inc.-qlti-soars%3A-stock-adds-7.9-in-session-tale-of-the-tape-2014-07-30", "https://www.nasdaq.com/articles/tesaro-tsro-slips-on-wider-than-expected-q2-loss-analyst-blog-2014-07-30", "https://www.nasdaq.com/articles/oncogenex-pharmaceuticals-ogxi-soars%3A-stock-up-8.2-tale-of-the-tape-2014-08-08", "https://www.nasdaq.com/articles/immunogen-imgn-soars%3A-stock-up-8.8-tale-of-the-tape-2014-07-21", "https://www.nasdaq.com/articles/merck-presents-positive-trial-results-cancer-drug-2014-06-02", "https://www.nasdaq.com/articles/abbvie-up-on-hcv-filing-in-canada-analyst-blog-2014-05-28", "https://www.nasdaq.com/articles/pre-market-earnings-report-may-12-2014-cxo-drh-evep-inn-zinc-bpi-enta-ticc-ino-flml-spns", "https://www.nasdaq.com/articles/ariads-q1-loss-narrows-analyst-blog-2014-05-08", "https://www.nasdaq.com/articles/wider-than-expected-loss-at-auxilium-analyst-blog-2014-05-06", "https://www.nasdaq.com/articles/endocyte-inc.-ecyt-in-focus%3A-stock-rises-5.6-tale-of-the-tape-2014-05-06", "https://www.nasdaq.com/articles/acelrx-pharmaceuticals-acrx-jumps%3A-stock-adds-11.7-in-session-tale-of-the-tape-2014-07-21", "https://www.nasdaq.com/articles/enanta-enta-sees-hammer-chart-pattern%3A-time-to-buy-tale-of-the-tape-2014-05-01", "https://www.nasdaq.com/articles/auxilium-pharma-cuts-guidance-analyst-blog-2014-04-30", "https://www.nasdaq.com/articles/synergy-pharmaceuticals-sgyp-jumps%3A-stock-up-10.9-tale-of-the-tape-2014-04-25", "https://www.nasdaq.com/articles/dr.-reddys-launches-generic-antara-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/abbvie-files-for-hcv-combination-therapy-in-u.s.-analyst-blog-2014-04-23", "https://www.nasdaq.com/articles/karyopharm-starts-phase-i-study-analyst-blog-2014-04-22", "https://www.nasdaq.com/articles/galectin-therapeutics-rises-on-gr-md-02-update-analyst-blog-2014-04-21", "https://www.nasdaq.com/articles/endo-international-plc-endp-jumps%3A-stock-rises-5.4-tale-of-the-tape-2014-05-02", "https://www.nasdaq.com/articles/enanta-enta-sees-hammer-chart-pattern%3A-time-to-buy-tale-of-the-tape-2014-05-01", "https://www.nasdaq.com/articles/auxilium-pharma-cuts-guidance-analyst-blog-2014-04-30", "https://www.nasdaq.com/articles/strength-seen-in-apricus-biosciences-apri%3A-stock-soars-18.9-tale-of-the-tape-2014-04-17", "https://www.nasdaq.com/articles/has-streamlined-fda-raised-value-drug-stocks-2014-04-17", "https://www.nasdaq.com/articles/positive-data-on-abbvies-hcv-program-analyst-blog-2014-04-14", "https://www.nasdaq.com/articles/commit-purchase-enanta-pharmaceuticals-35-earn-207-annualized-using-options-2014-03-10", "https://www.nasdaq.com/articles/abbvie-hcv-combination-therapy-data-looks-good-analyst-blog-2014-03-04", "https://www.nasdaq.com/articles/dr.-reddys-launches-generic-lunesta-analyst-blog-2014-04-17", "https://www.nasdaq.com/articles/sector-update-healthcare-shares-fairly-flat-acorda-q4-earnings-top-street-view-2014-02-13", "https://www.nasdaq.com/articles/enanta-enta-worth-watching%3A-stock-rises-13.4-tale-of-the-tape-2014-02-03", "https://www.nasdaq.com/articles/update-on-amarins-vascepa-analyst-blog-2013-12-27", "https://www.nasdaq.com/articles/update-on-nvos-victoza-analyst-blog-2013-12-26", "https://www.nasdaq.com/articles/sucampo-reports-data-analyst-blog-2013-12-26", "https://www.nasdaq.com/articles/eu-approves-actelions-opsumit-analyst-blog-2013-12-24", "https://www.nasdaq.com/articles/strength-seen-in-enanta-pharmaceuticals-enta%3A-stock-soars-28.6-tale-of-the-tape-2013-12-11", "https://www.nasdaq.com/articles/sector-update-healthcare-2014-02-13-0", "https://www.nasdaq.com/articles/good-news-for-apricus-from-italy-analyst-blog-2013-11-26", "https://www.nasdaq.com/articles/continuation-of-ariads-iclusig-in-eu-analyst-blog-2013-11-25", "https://www.nasdaq.com/articles/prescription-profit-zacks-industry-rank-analysis-2013-11-19", "https://www.nasdaq.com/articles/zacks-1-rank-additions-for-wednesday-tale-of-the-tape-2013-10-02", "https://www.nasdaq.com/articles/us-ipo-weekly-recap-seven-deals-price-six-new-filers-2013-03-25", "https://www.nasdaq.com/articles/one-us-ipo-planned-week-mar-25-2013-03-25", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-prices-ipo-14-low-end-range-2013-03-20", "https://www.nasdaq.com/articles/enanta-pharmaceuticals-enta-looks-good%3A-stock-adds-6.2-tale-of-the-tape-2013-11-26", "https://www.nasdaq.com/articles/us-ipo-calendar-heats-seven-deals-set-price-next-week-2013-03-12", "https://www.nasdaq.com/articles/biotech-enanta-pharmaceuticals-sets-terms-60-million-ipo-2013-03-05", "https://www.nasdaq.com/articles/9-us-ipos-planned-week-mar-18-2013-03-18"], "Content": []}